Borstkanker Onderzoek Groep

This phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims t…

This study looks at whether adding a CDK4/6 inhibitor (a targeted drug) to hormone therapy earlier or later works better for women with advanced hormone-receptor-positive breast cancer. About 1,050 women will receive either the drug combo first followed by another hormone therapy…

This phase 2 trial tests whether a combination of two drugs, ribociclib and letrozole, can replace standard chemotherapy for postmenopausal women with a common type of breast cancer (hormone receptor positive, HER2 negative). The study involves 100 participants who will receive e…

This phase 2 trial is testing whether doctors can safely reduce the amount of chemotherapy given to people with HER2-positive breast cancer by using imaging scans to guide treatment. The study involves 462 participants with stage II or III disease who receive a combination of dru…